Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16554128 | 1.00 | ZDHHC7 (0.45) | ZDHHC7EPHX1CA1CA2MAPT | |
| SCHEMBL16554621 | 1.00 | ZDHHC7 (0.45) | ZDHHC7EPHX1CA1CA2MAPT | |
| SCHEMBL12197297 | 0.90 | POLB (0.41) | CA1CA2MAPTHSD17B10POLB | |
| SCHEMBL3964196 | 0.86 | MAPT (0.50) | ZDHHC7EPHX1CA1CA2MAPT | |
| SCHEMBL3964199 | 0.86 | MAPT (0.50) | ZDHHC7EPHX1CA1CA2MAPT | |
| SCHEMBL27743948 | 0.86 | MAPT (0.50) | ZDHHC7EPHX1CA1CA2MAPT | |
| SCHEMBL17939720 | 0.84 | SMN1; SMN2 (0.51) | EPHX1MAPT | |
| SCHEMBL11800511 | 0.84 | SMN1; SMN2 (0.51) | EPHX1MAPT | |
| SCHEMBL11796686 | 0.84 | SMN1; SMN2 (0.51) | EPHX1MAPT | |
| SCHEMBL26122722 | 0.84 | SMN1; SMN2 (0.51) | EPHX1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9925528-B2 | Catalyst-controlled aliphatic C—H oxidations | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2018-03-27 | — | — | US | disclosed |
| US-20160214097-A1 | CATALYST-CONTROLLED ALIPHATIC C-H OXIDATIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2016-07-28 | — | — | US | disclosed |
| WO-2015035412-A1 | CATALYST-CONTROLLED ALIPHATIC C-H OXIDATIONS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2015-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160214097-A1 | CATALYST-CONTROLLED ALIPHATIC C-H OXIDATIONS | HMOX1, SOD3, CYC1 | ZDHHC7 219/4885EPHX1 1186/4885CA1 1569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.